These four medications are the big players in a class of medications called GLP-1 receptor agonists
When beginning GLP-1 medications, its normal to encounter mild side effects such as nausea , diarrhea , vomiting , or constipation as your body gets used to the treatment
These outcomes are similar to the results for other incretin-based therapies, namely, dulaglutide and semaglutide, which also showed a lack of relationship between the PK of GLP-1 receptor agonists and hepatic function [14,15,16]
Age-related degenerative changes in the spine account for 70% to 90% of all cases
Brain glucagon-like peptide-1 increases insulin secretion and muscle insulin resistance to favor hepatic glycogen storage
Most people experience minimal weight loss during those first four weeks, and that is completely expected